Nuclear Oncology

Posts Tagged ‘Chemotherapy’

We know that the Barbie doll house doll Mattel is timeless and is a benchmark for girls and not so girls. Therefore, an association of American parents have asked to design a signature Mattel Barbie with the same characteristics of the wrist but without hair.

They say well, girls with cancer do not lose self-esteem will be more motivated to overcome the disease especially when they lose their hair by the aggressive chemotherapy.
So far the campaign has been promoted by the popular social network Facebook and so far we can say that has more than 121,000 ‘I like’ as well ask after the bald Barbie, Mattel can design various accessories to dress such as hats, bandanas. More or less all the accessories can be designed for normal Barbies.

However, this initiative is derived from that last year, Mattel manufactured a bald Barbie for a four year old girl who had lost her hair after undergoing chemotherapy treatment. So now what is sought is that the company manufactures these dolls in series for girls suffering from cancer or have a family member with the disease and can lose all hope for living.

Of course not everyone is in favor of this initiative, there are those who think they can be counterproductive and not take this disease as it is, and even get to distort the true reality of people and girls who suffer.

The movement of course is led by parents who have a child with cancer, so talk to an informed and they are the ones who can really see the true state of girls, and if they believe that with a bald Barbie can give you a illusion may be included as a new therapy to overcome.

Cáncer drugs NHS (National Health System) has caused controversy in the country with his announcement to no longer provide patients with kidney cancer four drugs that can prolong his life arguing that they are too expensive.

But the response was immediate from patients with the disease have already stated that the decision taken by the National Institute for Health and Clinical Excellence, which will apply in England and Wales, condemn many patients to a ” early death. ”

Although not cure the disease when it is in an advanced stage, these drugs can extend life for patients with advanced kidney cancer by up to two years. The four drugs in question are Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus).

These modern treatments ‘target’, with a different mechanism of action of chemotherapy. Precisely these products are those that are revolutionizing worldwide funding of cancer treatments and forcing authorities to consider how to pay your large bill.

The NICE (a public body decides from 1999 on public funding of medical devices) as posing excessive spending for British health, estimated at 24,000 pounds (30,200 euros) per patient per year, and offer no good value for money.

“Although these drugs are clinically effective, regrettably in terms of costs can not be borne by the NHS resources,” said the director of NICE, Professor Peter Littlejohns,

In this regard, Pat Hanlon, the organization ‘Kidney Cancer UK’, dedicated to the fight against kidney cancer, said that the decision will have “a devastating impact on patients.”

And Professor John Wagstaff, Cancer Institute of South Wales, “This decision means that the UK will have the worst survival rates in Europe in this type of cancer.”